Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC

Yoshihiko Tomita; Sei Naito; Naoto Sassa; Atsushi Takahashi; Tsunenori Kondo; Takuya Koie; Wataru Obara; Yasuyuki Kobayashi; Jun Teishima; Masayuki Takahashi; Hideyasu Matsuyama; Takeshi Ueda; Kenya Yamaguchi; Takeshi Kishida; Ryoichi Shiroki; Takashi Saika; Nobuo Shinohara; Mototsugu Oya; Hiro omi Kanayama

doi:10.1016/j.clgc.2020.01.001

Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC

Yoshihiko Tomita, Sei Naito, Naoto Sassa, Atsushi Takahashi, Tsunenori Kondo, Takuya Koie, Wataru Obara, Yasuyuki Kobayashi, Jun Teishima, Masayuki Takahashi, Hideyasu Matsuyama, Takeshi Ueda, Kenya Yamaguchi, Takeshi Kishida, Ryoichi Shiroki, Takashi Saika, Nobuo Shinohara, Mototsugu Oya, Hiro omi Kanayama

Urology

Research output: Contribution to journal › Article › peer-review

14 Citations (Scopus)

Abstract

The aim of the present randomized controlled study was to compare the efficacy of sunitinib and sorafenib as first-line treatment of patients with metastatic clear cell renal cell carcinoma with favorable or intermediate Memorial Sloan Kettering Cancer Center risk. The median first progression-free survival was 8.7 and 7.0 months in the sunitinib and sorafenib groups, respectively (hazard ratio, 0.67; 95% confidence interval, 0.42-1.08).

Original language	English
Pages (from-to)	e374-e385
Journal	Clinical Genitourinary Cancer
Volume	18
Issue number	4
DOIs	https://doi.org/10.1016/j.clgc.2020.01.001
Publication status	Published - 08-2020

All Science Journal Classification (ASJC) codes

Oncology
Urology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clgc.2020.01.001

Cite this

Tomita, Y., Naito, S., Sassa, N., Takahashi, A., Kondo, T., Koie, T., Obara, W., Kobayashi, Y., Teishima, J., Takahashi, M., Matsuyama, H., Ueda, T., Yamaguchi, K., Kishida, T., Shiroki, R., Saika, T., Shinohara, N., Oya, M., & Kanayama, H. O. (2020). Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC. Clinical Genitourinary Cancer, 18(4), e374-e385. https://doi.org/10.1016/j.clgc.2020.01.001

@article{6f06a667036a496c9be0aac8e47cfffd,

title = "Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC",

abstract = "The aim of the present randomized controlled study was to compare the efficacy of sunitinib and sorafenib as first-line treatment of patients with metastatic clear cell renal cell carcinoma with favorable or intermediate Memorial Sloan Kettering Cancer Center risk. The median first progression-free survival was 8.7 and 7.0 months in the sunitinib and sorafenib groups, respectively (hazard ratio, 0.67; 95% confidence interval, 0.42-1.08).",

author = "Yoshihiko Tomita and Sei Naito and Naoto Sassa and Atsushi Takahashi and Tsunenori Kondo and Takuya Koie and Wataru Obara and Yasuyuki Kobayashi and Jun Teishima and Masayuki Takahashi and Hideyasu Matsuyama and Takeshi Ueda and Kenya Yamaguchi and Takeshi Kishida and Ryoichi Shiroki and Takashi Saika and Nobuo Shinohara and Mototsugu Oya and Kanayama, {Hiro omi}",

note = "Publisher Copyright: {\textcopyright} 2020 The Authors",

year = "2020",

month = aug,

doi = "10.1016/j.clgc.2020.01.001",

language = "English",

volume = "18",

pages = "e374--e385",

journal = "Clinical Genitourinary Cancer",

issn = "1558-7673",

publisher = "Elsevier Inc.",

number = "4",

}

Tomita, Y, Naito, S, Sassa, N, Takahashi, A, Kondo, T, Koie, T, Obara, W, Kobayashi, Y, Teishima, J, Takahashi, M, Matsuyama, H, Ueda, T, Yamaguchi, K, Kishida, T, Shiroki, R, Saika, T, Shinohara, N, Oya, M & Kanayama, HO 2020, 'Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC', Clinical Genitourinary Cancer, vol. 18, no. 4, pp. e374-e385. https://doi.org/10.1016/j.clgc.2020.01.001

TY - JOUR

T1 - Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk

T2 - Multicenter Randomized Trial CROSS-J-RCC

AU - Tomita, Yoshihiko

AU - Naito, Sei

AU - Sassa, Naoto

AU - Takahashi, Atsushi

AU - Kondo, Tsunenori

AU - Koie, Takuya

AU - Obara, Wataru

AU - Kobayashi, Yasuyuki

AU - Teishima, Jun

AU - Takahashi, Masayuki

AU - Matsuyama, Hideyasu

AU - Ueda, Takeshi

AU - Yamaguchi, Kenya

AU - Kishida, Takeshi

AU - Shiroki, Ryoichi

AU - Saika, Takashi

AU - Shinohara, Nobuo

AU - Oya, Mototsugu

AU - Kanayama, Hiro omi

PY - 2020/8

Y1 - 2020/8

N2 - The aim of the present randomized controlled study was to compare the efficacy of sunitinib and sorafenib as first-line treatment of patients with metastatic clear cell renal cell carcinoma with favorable or intermediate Memorial Sloan Kettering Cancer Center risk. The median first progression-free survival was 8.7 and 7.0 months in the sunitinib and sorafenib groups, respectively (hazard ratio, 0.67; 95% confidence interval, 0.42-1.08).

AB - The aim of the present randomized controlled study was to compare the efficacy of sunitinib and sorafenib as first-line treatment of patients with metastatic clear cell renal cell carcinoma with favorable or intermediate Memorial Sloan Kettering Cancer Center risk. The median first progression-free survival was 8.7 and 7.0 months in the sunitinib and sorafenib groups, respectively (hazard ratio, 0.67; 95% confidence interval, 0.42-1.08).

UR - http://www.scopus.com/inward/record.url?scp=85085351126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85085351126&partnerID=8YFLogxK

U2 - 10.1016/j.clgc.2020.01.001

DO - 10.1016/j.clgc.2020.01.001

M3 - Article

C2 - 32466961

AN - SCOPUS:85085351126

SN - 1558-7673

VL - 18

SP - e374-e385

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

IS - 4

ER -

Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this